Skip to main content

Biohaven Pharmaceutical Holding Co. Ltd. (BHVN)

NYSE: BHVN · IEX Real-Time Price · USD
135.21 3.63 (2.75%)
Oct 21, 2021 1:19 PM EDT - Market open
Market Cap8.69B
Revenue (ttm)189.53M
Net Income (ttm)-888.51M
Shares Out65.11M
EPS (ttm)-14.39
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume86,287
Open131.37
Previous Close131.58
Day's Range131.05 - 135.40
52-Week Range62.57 - 151.51
Beta0.99
AnalystsBuy
Price Target150.82 (+11.5%)
Est. Earnings DateNov 8, 2021

About BHVN

Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological diseases and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as id developing Rimegepant for preventive treatment of migraine and other non-migraine indications; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indi...

IndustryBiotechnology
IPO DateMay 4, 2017
CEOVlad Coric
Employees825
Stock ExchangeNYSE
Ticker SymbolBHVN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for BHVN stock is "Buy." The 12-month stock price forecast is 150.82, which is an increase of 11.55% from the latest price.

Price Target
$150.82
(11.55% upside)
Analyst Consensus: Buy

News

Biohaven (BHVN) Q3 Nurtec Preliminary Sales Top Expectations

Biohaven's (BHVN) sole marketable drug, Nurtec ODT reports preliminary sales for the third quarter, which beat expectations.

2 weeks ago - Zacks Investment Research

Biohaven Announces Preliminary 3Q2021 Net Product Revenue For NURTEC ODT, The First And Only Migraine Medication For ...

NEW HAVEN, Conn., Oct. 5, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.

2 weeks ago - PRNewsWire

Biohaven (BHVN) Phase III Multiple System Atrophy Study Fails

Biohaven's (BHVN) myeloperoxidase enzyme inhibitor, verdiperstat fails to statistically differentiate from placebo in improving disease progression in patients with multiple system atrophy in a late-sta...

3 weeks ago - Zacks Investment Research

Why Are Biohaven Shares Trading Lower On Monday?

Biohaven Pharmaceutical Holding Company Ltd (NYSE: BHVN) has announced results from a focused analysis of verdiperstat trial in verdiperstat in multiple system atrophy (MSA).  Verdiperstat did not diffe...

3 weeks ago - Benzinga

Biohaven Provides Update On Phase 3 Trial And Multiple System Atrophy (MSA) Program

NEW HAVEN, Conn., Sept. 27, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.

3 weeks ago - PRNewsWire

Biohaven Spotlights Nurtec® ODT (rimegepant), the only dual-therapy indicated for both the acute and preventive treat...

NEW HAVEN, Conn., Sept. 9, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.

1 month ago - PRNewsWire

Why Is Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Up 21.7% Since Last Earnings Report?

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) reported earnings 30 days ago.

1 month ago - Zacks Investment Research

Tuesday Afternoon Analyst Upgrades and Downgrades: SmileDirectClub, Squarespace, Victoria's Secret and More

With the trading day more than halfway over, the broad markets were mixed yet again, but this came with a couple of record highs.

Other symbols:SDCSQSPVSCOARCTOCUL
2 months ago - 24/7 Wall Street

Biohaven (BHVN) Q2 Earnings Miss, Nurtec Uptake Still Strong

Biohaven's (BHVN) sole approved drug, Nurtec ODT for treating migraine continues to demonstrate strong demand in the United States. Higher operating expense drags down the bottom line.

2 months ago - Zacks Investment Research

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Reports Q2 Loss, Tops Revenue Estimates

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) delivered earnings and revenue surprises of -16.61% and 0.02%, respectively, for the quarter ended June 2021.

2 months ago - Zacks Investment Research

Biohaven Pharma: Q2 Earnings Insights

Shares of Biohaven Pharma Hldgs (NYSE:BHVN) rose 0.8% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share decreased 2.75% year over year to ($2.62), which b...

2 months ago - Benzinga

Biohaven Reports Second Quarter 2021 Financial Results And Recent Business Developments

NEW HAVEN, Conn., Aug. 9, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.

2 months ago - PRNewsWire

Analysts Estimate Biohaven Pharmaceutical Holding Company Ltd. (BHVN) to Report a Decline in Earnings: What to Look O...

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

2 months ago - Zacks Investment Research

Biohaven's Nurtec® ODT Signs as Official Migraine Partner of Big Machine Music City Grand Prix Race

NASHVILLE, Tenn., July 29, 2021 /PRNewswire/ -- Biohaven Pharmaceuticals (NYSE:BHVN) announced today Nurtec® ODT (rimegepant) is the official migraine partner of the Big Machine Music City Grand Prix.

2 months ago - PRNewsWire

Biohaven to Report Second Quarter 2021 Financial Results and Recent Business Developments on August 9, 202

NEW HAVEN, Conn., July 28, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.

2 months ago - PRNewsWire

Will This Biopharma Company Continue to Crush It?

Migraine sufferers certainly hope so.

Other symbols:ABBV
3 months ago - The Motley Fool

Biohaven (BHVN) Q2 Nurtec Preliminary Sales Top Expectations

Biohaven Pharmaceutical's (BHVN) sole approved drug, Nurtec ODT's preliminary sales outperform expectations. Resultantly, share increase 13.6%.

3 months ago - Zacks Investment Research

Biohaven Rallies On Preliminary Nurtec Revenue Numbers: What Investors Need To Know

Biohaven Pharmaceutical Ltd. (NYSE:BHVN) released preliminary second-quarter revenue data for its drug Nurtec ODT on Wednesday.

3 months ago - Benzinga

Here's Why Biohaven Pharmaceutical Is Soaring Today

Preliminary sales figures for the company's new migraine drug were much better than expected.

3 months ago - The Motley Fool

Biohaven Announces Preliminary 2Q2021 Net Product Revenue For NURTEC ODT, The First And Only Migraine Medication For ...

NEW HAVEN, Conn., July 7, 2021 /PRNewswire/ --- Biohaven Pharmaceutical Holding Company Ltd.

3 months ago - PRNewsWire

Sosei Heptares Initiates Phase 1 Trial With Novel Small-Molecule CGRP Antagonist Under Collaboration With Biohaven

TOKYO and CAMBRIDGE, England, June 23, 2021 /PRNewswire/ -- Sosei Group Corporation ("the Company"; TSE: 4565) today announces that the first healthy subject has been dosed with HTL0022562 in a Phase 1 ...

3 months ago - PRNewsWire

Biohaven Appoints Kishen Mehta to Board of Directors

NEW HAVEN, Conn., June 17, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.

4 months ago - PRNewsWire

Eli Lilly To Test Injectable Migraine Med Against Biohaven's Oral Nurtec In Head-To-Head Study

Eli Lilly And Co (NYSE: LLY) will conduct a head-to-head study comparing once-monthly injectable Emgality (galcanezumab-gnlm) with Biohaven Pharmaceutical Holding Co Ltd's (NYSE: BHVN) Nurtec ODT (rimeg...

Other symbols:LLY
4 months ago - Benzinga

New Strong Sell Stocks for June 14th

CPB, MLAB, TMQ, CGAU, and BHVN have been added to the Zacks Rank #5 (Strong Sell) List on June 14, 2021

Other symbols:CGAUCPBMLABTMQ
4 months ago - Zacks Investment Research

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Up 35.3% Since Last Earnings Report: Can It Continue?

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) reported earnings 30 days ago.

4 months ago - Zacks Investment Research